MARK HILL: Open Payments
NPI 1053354084 · BRONX, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,254 in 171 payments from 27 companies in 2025. Trend: 2023 $5,783 · 2024 $4,595 · 2025 $5,254
Food & beverage: $5,065Education: $189
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 36 | $1,265 |
| Gilead Sciences, Inc. | 9 | $641 |
| Bayer Healthcare Pharmaceuticals Inc. | 13 | $437 |
| ViiV Healthcare Company | 7 | $313 |
| Corcept Therapeutics | 18 | $297 |
| Novo Nordisk Inc | 8 | $259 |
| GENZYME CORPORATION | 12 | $258 |
| GlaxoSmithKline, LLC. | 11 | $243 |
| Regeneron Healthcare Solutions, Inc. | 6 | $238 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $148 |
Products named: DUPIXENT, AIRSUPRA, Kerendia, TEZSPIRE, DOVATO, Korlym, FASENRA, Yeztugo.
Industry payments across NY — which companies pay providers there.
